CADL Candel Therapeutics, Inc.
USHealthcareAs of 2026-07-02
Why CADL matters now
Candel Therapeutics, Inc. (CADL) is a US stock in Healthcare. The latest InvestLog snapshot shows $9.83 with -0.51% on the session and $539.7M in market capitalization; recent performance reads 1-month +8.49% and YTD +47.08%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-8.9M, and EPS of $-0.14. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -10.7%.
The latest indexable market news headline is "Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $15.00; recent insider activity includes Loggia Nicoletta filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.75
P/S
0.00
EV/EBITDA
-5.23
DCF Value
$2.20
FCF Yield
-10.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-60.4%
ROA
-27.0%
ROIC
-28.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-8.9M | $-0.14 |
| Q4 2025 | $0.00 | $-29.5M | $-0.54 |
| FY 2025 | $0.00 | $-38.2M | $-0.72 |
| Q3 2025 | $0.00 | $-11.3M | $-0.21 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$15.00
Target (Median)
$15.00
Target Range
$15.00 - $15.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.48
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.